financetom
Business
financetom
/
Business
/
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
Nov 20, 2024 7:41 PM

05:02 PM EST, 11/20/2024 (MT Newswires) -- (Updates the stock change in the last paragraph.)

Nvidia ( NVDA ) reported fiscal Q3 non-GAAP earnings late Wednesday of $0.81 per diluted share, up from $0.40 a year earlier.

Analysts polled by FactSet expected $0.75 excluding some items.

Revenue in the three months ended Oct. 27 rose to $35.08 billion from $18.12 billion a year earlier.

Analysts surveyed by FactSet expected $33.17 billion.

The company expects fiscal Q4 revenue of $37.5 billion, plus or minus 2%. Analysts expect $37.09 billion.

Nvidia ( NVDA ) shares fell 0.7% in after-hours activity, paring earlier losses.

Price: 144.81, Change: -1.08, Percent Change: -0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck Initiates Phase 3 Trial to Evaluate Essential Thrombocythemia Treatment Candidate
Merck Initiates Phase 3 Trial to Evaluate Essential Thrombocythemia Treatment Candidate
Aug 27, 2024
07:18 AM EDT, 08/27/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday it has initiated a phase 3 clinical trial to evaluate bomedemstat, an investigational LSD1 inhibitor, for treating essential thrombocythemia in patients who have not previously received cytoreductive therapy. The trial, which is enrolling around 300 patients, will compare bomedemstat to the standard chemotherapy treatment, hydroxyurea. The primary...
Clear Blue Technologies Q2 Loss Narrows as Revenue Rises 35%
Clear Blue Technologies Q2 Loss Narrows as Revenue Rises 35%
Aug 27, 2024
07:15 AM EDT, 08/27/2024 (MT Newswires) -- Clear Blue Technologies International ( CBUTF ) overnight Monday said its second-quarter net loss narrowed by a third as revenue rose 35%. The company, which creates and manages power products and services for lower cost off-grid and hybrid energy, said the net loss fell to $1.4 million from $2 million last year. The...
BRIEF-AUO Announces Sale Of Plant In Taiwan To Micron Technology
BRIEF-AUO Announces Sale Of Plant In Taiwan To Micron Technology
Aug 27, 2024
Aug 27 (Reuters) - Auo: * ANNOUNCES SALE OF PLANT IN SOUTHERN TAIWAN TO MICRON TECHNOLOGY FOR T$7.4 BILLION ($232.7 MLN) * SAYS THE ASSET DISPOSAL WOULD YIELD ESTIMATED DIVESTMENT RETURN OF T$4.174 BILLION * SAYS ONE OF ITS UNITS HAS SOLD ANOTHER FACILITY TO MICRON TECHNOLOGY FOR T$700 MILLION, YIELDING DIVESTMENT RETURN OF T$544 MILLION Source text for Eikon:...
Eli Lilly Releases Single-Dose Vials of Obesity Drug Zepbound
Eli Lilly Releases Single-Dose Vials of Obesity Drug Zepbound
Aug 27, 2024
07:19 AM EDT, 08/27/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that single-dose vials of its Zepbound treatment for obesity in adults are now available for self-paying patients with on-label prescriptions, expanding access to the product. The vials come in 2.5-milligram and 5mg doses and are available through a new self-pay pharmacy division of the company's LillyDirect,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved